INBS

Company Overview — What Does INTELLIGENT BIO SOLUTIONS INC. Do?

GBS Inc. operates as a biosensor diagnostic technology company. It offers Saliva Glucose Biosensor that uses saliva to measure glucose non-invasively. The company also focuses on developing COV2 test, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumour markers, hormones, and nucleic acid diagnostic modalities. It has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd. INTELLIGENT BIO SOLUTIONS INC. (INBS) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Harry Simeonidis and employs approximately 10 people. With a market capitalization of $6M, INBS is one of the notable companies in the Healthcare sector.

INTELLIGENT BIO SOLUTIONS INC. (INBS) Stock Rating — Reduce (April 2026)

As of April 2026, INTELLIGENT BIO SOLUTIONS INC. receives a Reduce rating with a composite score of 34.8/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.INBS ranks #3,483 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, INTELLIGENT BIO SOLUTIONS INC. ranks #542 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

INBS Stock Price and 52-Week Range

INTELLIGENT BIO SOLUTIONS INC. (INBS) currently trades at $2.40. The stock lost $0.15 (5.9%) in the most recent trading session. The 52-week high for INBS is $24.90, which means the stock is currently trading -90.4% from its annual peak. The 52-week low is $0.54, putting the stock 346.1% above its annual trough. Recent trading volume was 16K shares, suggesting relatively thin trading activity.

Is INBS Overvalued or Undervalued? — Valuation Analysis

INTELLIGENT BIO SOLUTIONS INC. (INBS) carries a value factor score of 15/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.49x, versus the sector average of 2.75x. The price-to-sales ratio is 1.47x, compared to 1.66x for the average Healthcare stock.

At current multiples, INTELLIGENT BIO SOLUTIONS INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

INTELLIGENT BIO SOLUTIONS INC. Profitability — ROE, Margins, and Quality Score

INTELLIGENT BIO SOLUTIONS INC. (INBS) earns a quality factor score of 14/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -96.3%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -59.4% versus the sector average of -33.1%.

On a margin basis, INTELLIGENT BIO SOLUTIONS INC. reports gross margins of 41.5%, compared to 71.5% for the sector. The operating margin is -288.1% (sector: -66.1%). Net profit margin stands at -289.1%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -10.2% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

INBS Debt, Balance Sheet, and Financial Health

INTELLIGENT BIO SOLUTIONS INC. has a debt-to-equity ratio of 62.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 2.37x, indicating strong short-term liquidity.

INBS has a beta of 0.09, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for INTELLIGENT BIO SOLUTIONS INC. is 30/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

INTELLIGENT BIO SOLUTIONS INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, INTELLIGENT BIO SOLUTIONS INC. reported revenue of $4M and earnings per share (EPS) of $-2.82. Net income for the quarter was $-10M. Gross margin was 41.5%. Operating income came in at $-10M.

In Q2 2026, INTELLIGENT BIO SOLUTIONS INC. reported revenue of $896,774 and earnings per share (EPS) of $-2.82. Net income for the quarter was $-3M. Gross margin was 51.3%. Revenue grew 21.0% year-over-year compared to Q2 2025. Operating income came in at $-3M.

In Q1 2026, INTELLIGENT BIO SOLUTIONS INC. reported revenue of $1M and earnings per share (EPS) of $-0.35. Net income for the quarter was $-3M. Gross margin was 46.6%. Revenue grew 11.4% year-over-year compared to Q1 2025. Operating income came in at $-3M.

In FY 2025, INTELLIGENT BIO SOLUTIONS INC. reported revenue of $3M and earnings per share (EPS) of $-2.00. Net income for the quarter was $-11M. Gross margin was 40.8%. Revenue grew -1.9% year-over-year compared to FY 2024. Operating income came in at $-11M.

Over the past 8 quarters, INTELLIGENT BIO SOLUTIONS INC. has demonstrated a growth trajectory, with revenue expanding from $3M to $4M. Investors analyzing INBS stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

INBS Dividend Yield and Income Analysis

INTELLIGENT BIO SOLUTIONS INC. (INBS) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

INBS Momentum and Technical Analysis Profile

INTELLIGENT BIO SOLUTIONS INC. (INBS) has a momentum factor score of 60/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 36/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 68/100 reflects moderate short selling activity.

INBS vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, INTELLIGENT BIO SOLUTIONS INC. (INBS) ranks #542 out of 838 stocks based on the Blank Capital composite score. This places INBS in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing INBS against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full INBS vs S&P 500 (SPY) comparison to assess how INTELLIGENT BIO SOLUTIONS INC. stacks up against the broader market across all factor dimensions.

INBS Next Earnings Date

No upcoming earnings date has been announced for INTELLIGENT BIO SOLUTIONS INC. (INBS) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy INBS? — Investment Thesis Summary

The quantitative profile for INTELLIGENT BIO SOLUTIONS INC. suggests caution. The quality score of 14/100 flags below-average profitability. The value score of 15/100 indicates premium valuation. Price momentum is positive at 60/100, suggesting the trend favors buyers. High volatility (stability score 30/100) increases portfolio risk.

In summary, INTELLIGENT BIO SOLUTIONS INC. (INBS) earns a Reduce rating with a composite score of 34.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on INBS stock.

Related Resources for INBS Investors

Explore more research and tools: INBS vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare INBS head-to-head with peers: INBS vs AZN, INBS vs SLGL, INBS vs VMD.